PremiumStock Analysis & IdeasOppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks Y-mAbs Therapeutics initiated with a Buy at Brookline on Danyelza potential Y-mAbs Therapeutics initiated with a Buy at Brookline PremiumThe FlyY-mAbs Therapeutics backs FY24 revenue view $87M-$95M, consensus $91.67M Is YMAB a Buy, Before Earnings? Y-mAbs Partners with Nobelpharma for Japan Expansion PremiumThe FlyY-mAbs Therapeutics initiated with an Overweight at Cantor Fitzgerald Y-mAbs Therapeutics price target lowered to $11 from $12 at Morgan Stanley Y-mAbs Therapeutics price target lowered to $25 from $26 at BMO Capital